David Dally
Vorstandsvorsitzender bei MerLion Pharmaceuticals Pte Ltd.
Profil
David Dally is currently the Chief Executive Officer at MerLion Pharmaceuticals Pte Ltd.
since 2007 and the Chief Financial Officer & Director at Engitix Ltd.
since 2018.
Previously, he held positions as the Chief Executive Officer at Reproductive Sciences Ltd., Principal at Ernst & Young LLP, Vice President-Finance at Amersham Pharmacia Biotech, Inc., Chief Financial Officer & Secretary at KuDOS Pharmaceuticals Ltd., and Chief Financial Officer at Dyson, Inc.
Aktive Positionen von David Dally
Unternehmen | Position | Beginn |
---|---|---|
MerLion Pharmaceuticals Pte Ltd.
MerLion Pharmaceuticals Pte Ltd. Miscellaneous Commercial ServicesCommercial Services MerLion Pharmaceuticals Pte Ltd. provides drug discovery and development services. It focuses on developing its lead antibacterial candidate, finafloxacin, through early and mid-stage clinical trials. The company was founded in 2002 and is headquartered in Singapore. | Vorstandsvorsitzender | 01.03.2007 |
Engitix Ltd.
Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | Finanzdirektor/CFO | 01.11.2018 |
Ehemalige bekannte Positionen von David Dally
Unternehmen | Position | Ende |
---|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Amersham Pharmacia Biotech, Inc. | Finanzdirektor/CFO | - |
KuDOS Pharmaceuticals Ltd.
KuDOS Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KuDOS Pharmaceuticals Ltd. discovers and develops pharmaceutical products. Its products are used to treat DNA damage sensing, signaling, viral disease, ischaemia, and repair to address unmet medical needs in cancer treatment. The company was founded by Stephen Jackson on December 12, 1997 and is headquartered in Cambridge, UK. | Finanzdirektor/CFO | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
KuDOS Pharmaceuticals Ltd.
KuDOS Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KuDOS Pharmaceuticals Ltd. discovers and develops pharmaceutical products. Its products are used to treat DNA damage sensing, signaling, viral disease, ischaemia, and repair to address unmet medical needs in cancer treatment. The company was founded by Stephen Jackson on December 12, 1997 and is headquartered in Cambridge, UK. | Health Technology |
MerLion Pharmaceuticals Pte Ltd.
MerLion Pharmaceuticals Pte Ltd. Miscellaneous Commercial ServicesCommercial Services MerLion Pharmaceuticals Pte Ltd. provides drug discovery and development services. It focuses on developing its lead antibacterial candidate, finafloxacin, through early and mid-stage clinical trials. The company was founded in 2002 and is headquartered in Singapore. | Commercial Services |
Amersham Pharmacia Biotech, Inc. | Commercial Services |
Engitix Ltd.
Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | Commercial Services |